Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation

Inclusion Criteria: * Age ≥18 years or greater * Preoperative diagnosis of PJI of the hip or knee per the 2018 Definition of Periprosthetic Hip and Knee Infection * Chronic PJI (symptoms lasting at least 4 weeks) per Tsukayama et al. * Medical clearance for surgery * Physical and mental ability and willingness to comply with the protocol, including the ability to read and complete required forms, and willingness and ability to adhere to the scheduled follow-up visits and requirements of the protocol Exclusion Criteria: * Late acute hematogenous infection per Tsukayama et al. * Patients for whom a two-stage exchange arthroplasty is not indicated * Sepsis * Previously failed single- or two-stage revision arthroplasty for PJI (aseptic revision, polyethylene liner exchange, and/or irrigation and debridement with component retention is allowed) * Patients with PJI of more than one joint * Patients on chronic antibiotic therapy (≥ 6 months duration) * Patients who require therapeutic anticoagulation * Patients on antiplatelet therapy for whom withholding antiplatelet therapy for any amount of time is contraindicated * Patients with renal insufficiency/failure (serum creatinine ≥ 2.0 mg/dl) * Patients with uncontrolled diabetes, defined as: hemoglobin A1C levels \> 8.0% * Patients on immunosuppressive therapy, chemotherapy for malignant disease, or glucocorticoid therapy (e.g. prednisone ≥ 10 mg/day). * Patients with immunodeficiency (e.g., splenectomy; sickle cell anemia; Stage 3 HIV; primary humoral, bone marrow, or other transplantation.) * Anticipated or potential patient relocation that may interfere with follow-up examinations * Allergy to vancomycin HCl or tobramycin sulfate (Note: prior history of Red Man's syndrome is not considered an allergy) * Patients who are pregnant or planning to become pregnant * Patients in whom negative pressure wound therapy is contraindicated * Patients infected with pathogens that are not considered susceptible to vancomycin HCl or tobramycin sulfate, as per the Investigator's opinion * Breastfeeding at screening visit * Patients who are prisoners * Participation in another clinical trial of another Investigational Drug or Investigational Device within the past 30 days